[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

144

1 you 25 percent effect. The two together gave you a 50
2 percent effect.
3 And it may be that based on biological
4 rationale and various other data, there could be
5 experts that could tell us which of these things could
6 be tested in what is classically called factor-real
7 designs. So that's another option to consider.
8 I'm very enthusiastic about much of what
9 Mark put forward, not everything yet, but --
10 CO-CHAIRMAN CARPENTER: Thank you very
11 much, Dr. Yusuf, for those very thoughtful comments.
12 I think Mr. Dobson has --
13 MR. DOBSON: I wanted to probably disagree
14 a little bit. I think that any trial of this vaccine
15 or these vaccines, which I think it's absolutely
16 critical that it's a comparison trial, that not a
17 single agent trial be done for both efficiency and the
18 fact that I don't think that we should allow the fate
19 of the MicroGenesys gp 160 vaccine to either make or
20 break vaccine therapy. I think it's very important
21 that we test it.
22 I think it's also important that we have
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]